Search results for "CHRONIC HEPATITIS"
showing 10 items of 159 documents
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.
2011
Summary. The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with histological features and with sustained virological response (SVR) in patients with genotype 1 chronic hepatitis C(G1CHC). Three hundred and forty consecutive patients with G1CHC were considered. All had a liver biopsy scored by one pathologist for staging and grading (Scheuer), and graded for steatosis, which was considered moderate–severe if ≥30%. Anthropometric an…
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations
2011
BACKGROUND AND AIMS: There are contrasting results in studies of cardiovascular risk in patients with genotype 1 chronic hepatitis C (G1 CHC). We evaluated the prevalence of carotid atherosclerosis compared with a control population in order to assess the potential association between atherosclerosis, host and viral factors, and liver histological features. MATERIALS AND METHODS: One hundred seventy-four consecutive biopsy-proven G1 CHC patients were evaluated by anthropometric and metabolic measurements. One hundred seventy-four patients attending an outpatient cardiology unit were used as controls. Intima-media thickness (IMT) and carotid plaques, defined as focal thickening of > 1.3 mm a…
Definition of response to antiviral therapy in chronic hepatitis C
2000
Assessment of health-related quality of life of chronic hepatitis C patients in Latvia
2019
Šā pētījuma mērķis ir novērtēt hroniska C hepatīta pacientu ar veselību saistīto dzīves kvalitāti Latvijā, izmantojot anketu par aknu slimībām, un izpētīt jomas, kurās visbiežāk ir traucēta ar veselību saistītā dzīves kvalitāte. Šajā pētījumā tiks arī apskatīti faktori, kas saistīti ar hroniska C hepatīta pacientu dzīves kvalitāti. Šis ir prospektīvs novērojumu pētījums. Hronisko aknu slimību anketa tika pielāgota un izsniegta Latvijas Infektoloģijas centra pacientiem, kam ir seroloģiski apstiprināts hronisks C vīrushepatīts. Kontroles grupā tika iekļauti pieauguši latvieši, kuriem nav diagnosticēts hronisks C vīrushepatīts Pētījuma tika iekļauti 80 pacienti vecumā no 25 līdz 78 gadiem (vid…
Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2° and ribavirin
2009
SUMMARY. Guidelines for the treatment of patients infected with hepatitis C virus of genotypes 2 and 3 (HCV-2 and HCV-3, respectively) recommend a 24-week course of Peginterferon (Peg-IFN) alpha-2a combined with ribavirin, despite 50% of patients in registration trials attaining a sustained virologic response (SVR) following Peg-IFN alpha-2a monotherapy. The aim of this study was to delineate patient characteristics that might help to identify individuals likely to benefit from ribavirin discontinuation. One hundred and forty-four HCV-2- and HCV-3-infected patients initiated Peg-IFN alpha-2a (180 lg ⁄ week) and ribavirin (1000 or 1200 mg⁄ day); those with viral clearance at week 4 were rand…
Epidemiological evolution of Chronic Hepatitis Delta in Italy. An analysis of the Master-B cohort
2014
Weight-based dosing: Which impact on efficacy and safety of therapy?
2004
Abstract Pegylated interferons (PEG-IFNs) in combination with ribavirin represent the most recent advance in the treatment of patients withchronic hepatitis C (CHC): two large clinical trials have shown a superior efficacy in clearing HCV in almost 60% of treated naive patients. Responses to antiviral treatment of CHC vary according to both viral and host factors. Managing patients with CHC infection requires individualised treatment strategies to optimise outcomes. Several landmark publications on PEG-IFNs have reported that weight is a significant predictive factor for SVR in the treatment of CHC with fixed-dose drug administration. With fixed-dose treatment, there is a direct correlation…
Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis
2017
Background The joint effect of the interaction of alcohol intake, hepatitis B virus (HBV) and hepatitis C virus (HCV) on the risk of cirrhosis is still unexplored because a large sample size is required for this investigation. Objective Evaluation of interaction of HBV, HCV and alcohol abuse on the risk of cirrhosis. Design We analysed 12,262 consecutive patients with chronic liver disease of various aetiologies referring to 95 Italian liver units in 2001 or 2014. To evaluate the interaction between alcohol abuse, HBV infection, and HCV infection, patients unexposed to either factors were used as reference category. Adjustment for BMI and age was done by multiple logistic regression analysi…
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohor…
2015
Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the i…